Posts

Showing posts from January, 2022

Stuck Between Rock And A Hard Place: Prince Andrew's Sexual Assault Case

Image
  US Sexual Assault Case: After New York Judge ruled that Virginia Giuffre's civil lawsuit against the royal can proceed, the Prince's attorneys can ask the Second Circuit Court of Appeals to overturn his decision New York:  Britain's Prince Andrew is stuck between a rock and a hard place: He either settles out of court with his sexual assault accuser or endures a grilling by lawyers under oath, experts say. After New York judge Lewis Kaplan ruled Wednesday that Virginia Giuffre's civil lawsuit against the royal can proceed, AFP takes a look at the possible next steps in the case rocking Britain's monarchy. Can Andrew appeal? Yes. His attorneys can ask the Second Circuit Court of Appeals to overturn Kaplan's decision. If that fails then theoretically they could take the case to the US Supreme Court, however legal analysts are skeptical about whether justices would choose to hear it. An appeal would delay proceedings. The clock is already ticking on the submissio

AstraZeneca, Given As Booster, Gives Higher Antibodies Against Omicron

Image
  The increased response was seen in people who were previously vaccinated with either Vaxzevria or an mRNA vaccine, the drugmaker said, adding that it would submit this data to regulators worldwide given the urgent need for boosters. AstraZeneca said on Thursday preliminary data from a trial it conducted on its COVID-19 shot, Vaxzevria, showed it generated a higher antibody response against the Omicron variant and others, including Beta, Delta, Alpha and Gamma, when given as a third booster dose. The increased response was seen in people who were previously vaccinated with either Vaxzevria or an mRNA vaccine, the drugmaker said, adding that it would submit this data to regulators worldwide given the urgent need for boosters. AstraZeneca has developed the vaccine with researchers from the University of Oxford, and lab studies last month found a three-dose course of Vaxzevria was effective against the rapidly spreading new variant. The data is the first released by the company from its